Inactive Instrument

Neon Therapeutics, Inc.

Equities

US64050Y1001

Biotechnology & Medical Research

Neon Therapeutics, Inc. Announces Resignation of Julian Adams as Member of the Board and All Committees of the Board

August 31, 2018 at 06:09 am

On August 28, 2018, Julian Adams, Ph.D. informed the board of directors of Neon Therapeutics, Inc. of his resignation as a member of the Board and all committees of the Board, effective as of August 28, 2018.

Latest news about Neon Therapeutics, Inc.

Neon Therapeutics, Inc. Announces Management Changes	20-05-06	CI
Neon Therapeutics, Inc.(NasdaqGS:NTGN) dropped from S&P TMI Index	20-05-06	CI
BioNTech SE completed the acquisition of Neon Therapeutics, Inc. from Third Rock Ventures, LLC and others.	20-05-05	CI
Transcript : Neon Therapeutics, Inc. - Shareholder/Analyst Call	20-05-04
Neon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-01	CI
Neon Therapeutics, Inc. Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01	20-04-30	CI
Neon Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	20-03-02	CI
BioNTech SE entered into an Agreement to acquire Neon Therapeutics, Inc. from Third Rock Ventures, LLC and others for $73.6 million.	20-01-15	CI
Neon Therapeutics, Inc. Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01	19-12-18	CI
Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs; to Reduce Workforce by Approximately 24% of Current Headcount	19-11-20	CI
Neon Therapeutics Intends to Explore Strategic Alternatives	19-11-20	CI
Neon Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Neon Therapeutics, Inc. Presents Updated Data at the Society for Immunotherapy of Cancer's 34th Annual Meeting in National Harbor, MD	19-11-08	CI
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens	19-09-05	CI
Neon Therapeutics, Inc. Provides Business Update	19-08-06	CI
Neon Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-06	CI
Transcript : Neon Therapeutics, Inc. - Special Call	19-07-15
Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers	19-07-15	CI
Neon Therapeutics To Seek Acquisitions	19-07-01	CI
Transcript : Neon Therapeutics, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-15-2019 05:01 PM	19-05-15
Neon Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019; Provides Clinical Update	19-05-13	CI
Neon Therapeutics Announces Completion of Enrollment in Phase 1b NT-002 Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer	19-04-08	CI
Neon Therapeutics, Inc. Presents Updated Data from Ongoing Phase 1B Nt-001 Clinical Trial of Personal Neoantigen Vaccine NEO-PV-01	19-03-31	CI
Neon Therapeutics, Inc. Reports Consolidated Financial Results for the Fourth Quarter and Twelve Months of 2018	19-03-11	CI
Neon Therapeutics to Present At the American Association for Cancer Research Annual Meeting	19-02-27	CI

Chart Neon Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Neon Therapeutics is a clinical-stage immuno-oncology company. The Company is focused on developing therapeutics leveraging neoantigen biology to treat cancer. The Company's neoantigen-based product engine allows it to develop multiple treatment modalities, including vaccines and thymus (T) cell therapies targeting both personalized and shared neoantigens. The Company's neoantigen-based product engine targets both neoantigens that are specific to individual patients, as well as neoantigens that are shared across patients and tumor types. The Company's NEO-PV-01 program is a personalized neoantigen vaccine. NEO-PV-01 utilizes an epitope computational engine called Real-time Epitope Computation for Oncology (RECON). The Company's NEO-PTC-01 is an Adoptive T Cell Therapy. NEO-PTC-01 uses immunogens in co-culture with T cells and monocyte-derived dendritic cells from patients in order to ex vivo stimulate autologous T cells to respond against neoantigen targets.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+19.33%	125B
REGENERON PHARMACEUTICALS, INC.	+13.95%	108B
BIONTECH SE	-3.53%	24.57B
ARGENX SE	+3.26%	22.82B
GENMAB A/S	-11.04%	18.19B
WUXI APPTEC CO., LTD.	-41.48%	16.54B
BEIGENE, LTD.	-12.62%	16.5B
NEUROCRINE BIOSCIENCES, INC.	+0.99%	13.39B
SAREPTA THERAPEUTICS, INC.	+21.79%	11.1B

Bio Therapeutic Drugs